Profound Medical Corp PROF

Global debt costs are climbing, with interest bills now larger than many governments spend on AI itself. That squeeze on public budgets is pushing attention toward private companies building real AI tools that healthcare providers can pay for and use today. Canadian AI in medicine sits right in that conversation. This article breaks down three stocks from our AI healthcare screen that show how this theme is playing out in practice. The stocks covered below are just a sample from this theme,...

Canada’s Ivey PMI recently hit a multi year high, hinting that businesses are spending again on tools that cut costs and raise productivity. That backdrop puts artificial intelligence in healthcare on many watchlists. AI can help Canadian hospitals and drug developers do more with limited budgets. This article walks through three AI focused healthcare stocks from our screener that could interest investors watching this shift. The stocks below are just a sample from this theme, and the full...

TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City. The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available. A

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the appointment of Richard Fabian as its new President, effective immediately. Mr. Fabian succeeds Mathieu Burtnyk, PhD, who has shifted to the newly created position of Chief Technology Officer. Mr. Fabian has an accomplished history of sales, m

Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per dayTORONTO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today announced the introduction of its latest Treatment Delivery Consol (“TDC”) software. The new TDC software, which is being dep

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as the Company’s Chief Financial Offi

A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support Alt attribution: Profound Medical Corp. TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today announced the launch of Let's Huddle, a global patient communit

Moby summary of Profound Medical Corp.'s Q2 2026 earnings call

Profound Medical (NASDAQ:PROF) reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product shipments completed in July rather than June. Corporate Controller Matthew Sobczyk

Despite a $3.1 million shipment timing issue, Profound Medical Corp (PROF) posts strong commercial momentum with a record July order month and expanding payer coverage.

– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and reimbursement momentum continues – – Company reiterates full-year 2026 revenue guidance – – Announces first employer owned health plans to list the TULSA Procedure™ as a covered service – TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Pro

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S

– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month –TORONTO, July 24, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced new data from the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure™ wit

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter

TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be highlighted in several presentations by leading physicians at the upcoming Society of Robotic Surgery (“SRS”) Annual Meeting to be held in Fort Lauderdale, FL, July 23-26, 2026.* MAIN CONGRESS SESSIONS Real-world Outcomes after MRI-guided Transurethral Ultrasound

Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental […]